IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: M. J. Renzi et al. Art Unit: 9072

Serial No.: 10/810,755 Confirmation No: 9072

Filed: March 26, 2004 Examiner: R.J. Deberry

For : USE OF ERYTHROPOIETIN IN STROKE RECOVERY

I hereby certify that this correspondence is being transmitted via The Office electronic filing system in accordance with 37 CFR 1.6(a)(4)

> May 14, 2007 (Date of Transmission)

Yunling Ren (Name of applicant, assignee, or Registered Representative)

/Yunling Ren/ (Signature)

May 14, 2007 (Date of Signature)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Dear Sir:

This copy is supplemental to the Information Disclosure Statement mailed on November 22, 2005.

Pursuant to 37 C.F.R. $\S1.56$ and in accordance with 37 C.F.R. $\S\S1.97-1.98$, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. $\S1.56$ (b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this

information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

In accordance with §1.97(b), since this Information \boxtimes Disclosure Statement is being filed either within three months of the filing date of the above-identified national application (other than a continued prosecution application under §1.53(d)), within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of a request for continued examination under §1.114, no additional fee is required. In accordance with §1.129(a), this Information Disclosure Statement is being filed in connection with \prod the first or ☐second After Final Submission, therefore: Statement in Accordance with §1.97(e) (attached); or Please charge Deposit Account No. 10-П 0750/ / the fee of \$180.00 as set forth in \$1.17(p). In accordance with \$1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, or an

action that otherwise closes prosecution and that it is		
accompanied by one of:		
	Statement in Accordance with §1.97(e)	
	(attached); or	
	Please charge Deposit Account No. 10-	
1	0750/ / the fee of $$180.00$ as set forth	
	in §1.17(p).	
\square In accordance with §1.97(d), this Information		
Disclosure Statement is being filed after the mailing date of		
either a Final Action under §1.113 or a Notice of Allowance		
under §1.311 but before the payment of the Issue Fee.		
Applicant(s) hereby petition(s) for consideration of this		
Information Disclosure Statement. Included are: Statement in		
Accordance with §1.97(e) as set forth below and the fee of		
\$180.00 as set forth in $$1.17(p)$.		
Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.		
Copies of references listed on the attached Form PTO-		
1449 are enclosed herewith EXCEPT THAT:		
	In view of the voluminous nature of references [list as appropriate], and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.	
	If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.	
☐ Copies of only foreign patent documents and non-patent		
literature are enclosed in accordance with 37 CFR 1.98 (a)(2).		

igties There are no list	ed references which are not in the
English language.	
☐ The relevance of in the English language is	those listed references which are not as follows:
_	es of search report(s) from ation(s), which are listed on the PEP 609 D.
-	erences listed on the search pt for those previously cited in an
	following non-published pending ay be deemed relevant, which are ission Under MPEP 609.06.
	ciency or credit any overpayment to /PRD2052/YR. This form is submitted
	Respectfully submitted,
Johnson & Johnson One Johnson & Johnson Plaza	_/Yunling_Ren/ Yunling_Ren Reg. No. 47,019 Attorney for Applicants

One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003
(732) 524-3385
DATED: May 14, 2007